Edition 12

The FDA granted accelerated approval to Atezolizumab (Tecentriq) plus nanoparticle albumin-bound (nab) Paclitaxel (Abraxane) for unresectable locally advanced…


Read More

Edition 11

In a recent clinical trial, researchers have found promising clinical activity of Pembrolizumab with Trastuzumab in patients with PD-L1 positive,…


Read More

Edition 10

In a recent clinical trial, researchers found that patients with a higher tumor mutational burden, T cell inflamed gene expression profile and PDL-1 expression…


Read More

Edition 09

The FDA approved Osimertinib (Tagrisso) for the first-line treatment of metastatic NSCLC with (EGFR) exon 19 deletions or exon 21 L858R mutations (Read More).…


Read More

Edition 08

The FDA granted approval to Gilteritinib for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation…


Read More

Edition 07

A prospective cohort study of 323 patients with metastatic NSCLC showed marked increase in detection of therapeutically targetable mutations and improved…


Read More

Edition 06

The targeted therapy Venetoclax (Venclexta) can now be used for a broader group of patients with chronic lymphocytic leukemia (CLL). The U.S. Food and Drug…


Read More

Edition 05

The targeted therapy Venetoclax (Venclexta) can now be used for a broader group of patients with chronic lymphocytic leukemia (CLL). The U.S. Food and Drug…


Read More

Edition 04

The US Food and Drug Administration (FDA) has approved Pembrolizumab (Keytruda) for patients with recurrent or metastatic cervical cancer with disease…


Read More